The Vitalyst system addresses a critical medical emergency where the heart fails to circulate sufficient blood to the body's vital organs. By focusing on a minimally invasive delivery method, the companies aim to improve both the safety profile and clinical efficacy of current circulatory support tools. Nicholas Galakatos, head of Blackstone Life Sciences, noted that the technology holds the potential to significantly outperform existing devices in this sector. This agreement establishes a new collaborative framework for Boston Scientific to bring specialized cardiac equipment to market through external funding.
Blackstone Backs Boston Scientific Heart Pump in $455M Deal
A $455 million capital infusion from Blackstone Life Sciences will accelerate the development of the Vitalyst heart pump, marking the first partnership between the private equity firm and Boston Scientific. The device seeks to provide mechanical circulatory support for patients suffering from cardiogenic shock without requiring invasive open-heart surgery.
Comments (0)
No comments yet. Be the first!